Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis

Nozomi Imai(Yokohama City University), Tatsuo Hashimoto(Yokohama City University), Minoru Kihara(Yokohama City University), Shin‐ichiro Yoshida(Yokohama City University), Ichiro Kawana(Yokohama City University), Takuya Yazawa(Yokohama City University), Hitoshi Kitamura(Yokohama City University), Satoshi Umemura(Yokohama City University)
Laboratory Investigation
February 1, 2007
10.1038/labinvest.3700504
Cited by 83Open Access
Full Text

Abstract

Related Papers

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
K. Jin Kim, Bing Li, Jane Winer et al.|Nature|1993|3.6k
Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination
Takayasu Suganuma, Kazuhiko Ino, Kiyosumi Shibata et al.|Clinical Cancer Research|2005|238
Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways
Radia Tamarat, Jean‐Sébastien Silvestre, Micheline Durie et al.|Laboratory Investigation|2002|225
Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture
John S. Bertram, Przemysław Janik|Cancer Letters|1980|219
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Yumiko Shibouta, Yasuhiro Inada, M Ojima et al.|Journal of Pharmacology and Experimental Therapeutics|1993|213